Investment Summary |
|
|---|---|
| Date | 2007-01-05 |
| Target | Serono S.A. |
| Sector | Life Science |
| Investor(s) | Merck |
| Deal Type | Stake Purchase |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1668 |
| Sector | Diversified |
| Employees | 64,011 |
| Revenue | 21.2B EUR (2024) |
Merck is a science and technology company in healthcare, life science, and performance materials. It develops technologies that improve and enhance life, from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. Merck was founded in 1668 and is based in Darmstadt, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 26 |
| Sector: Life Science M&A | 1 of 12 |
| Type: Stake Purchase M&A Deals | 1 of 2 |
| Country: Germany M&A | 1 of 6 |
| Year: 2007 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2004-10-27 |
Merck KGaA - 5-HT2 Novel Compound
Germany Merck KGaA - 5-HT2 Novel Compound is a antagonist compound EMD 281014, a potential breakthrough treatment for insomnia. EMD 281014 is currently in Phase 1 clinical trials. Insomnia affects more than 164 million people worldwide, including more than 49 million with chronic insomnia. |
Sell | €23M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-05-12 |
Merck Generics
Germany Merck Generics is a generic and specialty pharmaceutical company. |
Sell | €4.9B |
